Microbial Biomarkers for NAFLD Risk and Gut Microbiota
Fecal Microbial Biomarkers for Non-Alcoholic Fatty Liver Disease
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology identifies fecal microbial biomarkers that differentiate between NAFLD patients and healthy individuals, revealing significant variations in gut microbiota composition. Specifically, a particular bacterium is significantly decreased in obese NAFLD patients, suggesting its role as a potential biomarker for risk evaluation and a therapeutic target. Applications include diagnostic tools to assess NAFLD risk and the development of probiotic dietary supplements to prevent or improve NAFLD conditions. Research on mice demonstrates that healthy microbiota reduces intrahepatic lipid accumulation, validating its therapeutic potential. Protected by a submitted US patent application, this innovation addresses a critical need in managing the growing global burden of NAFLD.
IP Type or Form Factor: Patent Pending; Discovery & Research; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Diagnostics & Screening; Biotechnology
